Upregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes

Journal of Clinical Investigation

Volumn 112, Issue 10, 2003, Pages 1521-1532

  Hennige, Anita M ^a   Burks, Deborah J ^a   Ozcan, Umut ^b   Kulkarni, Rohit N ^b   Ye, Jing ^a   Park, Sunmin ^a   Schubert, Markus ^a   Fisher, Tracey L ^a   Dow, Matt A ^a   Leshan, Rebecca ^a   Zakaria, Mark ^a   Mossa Basha, Mahmud ^a   White, Morris F ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; SOMATOMEDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; GENE; GENE EXPRESSION REGULATION; INSULIN METABOLISM; INSULIN RELEASE; IRS2 GENE; MOUSE; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TRANSGENIC MOUSE;

EID: 0345618266     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI18581     Document Type: Article

References (55)

1. Zimmet, P., Alberti, K.G., and Shaw, J. 2001. Global and societal implications of the diabetes epidemic. Nature. 414:782-787.
2. Taylor, S.I., Accili, D., and Imai, Y. 1994. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes. 43:735-740.
3. Kahn, S.E. 2003. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 46:3-19.
4. Ehrmann, D.A., et al. 2002. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia. 45:509-517.
5. Kitamura, T., Kahn, C.R., and Accili, D. 2003. Insulin receptor knockout mice. Annu. Rev. Physiol. 65:313-332.
6. Yenush, L., and White, M.F. 1997. The IRS-signalling system during insulin and cytokine action. Bioessays. 19:491-500.
7. Kido, Y., Nakae, J., and Accili, D. 2001. Clinical review 125: the insulin receptor and its cellular targets. J. Clin. Endocrinol. Metab. 86:972-979.
8. Garofalo, R.S., et al. 2003. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ. J. Clin. Invest. 112:197-208. doi:10.1172/JCI200316885.
9. Withers, D.J., et al. 1998. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 391:900-904.
10. Kitamura, T., et al. 2002. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic β cell growth. J. Clin. Invest. 110:1839-1847. doi:10.1172/JCI200216857.
11. Kulkarni, R.N., et al. 2002. beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat. Genet. 31:111-115.
12. Kulkarni, R.N., et al. 1999. Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 96:329-339.
13. Xuan, S., et al. 2002. Defective insulin secretion in pancreatic β cells lacking type 1 IGF receptor. J. Clin. Invest. 110:1011-1019. doi: 10.1172/ JCI200215276.
14. Bonner-Weir, S. 2000. Islet growth and development in the adult. J. Mol. Endocrinol. 24:297-302.
15. Avruch, J. 1998. A signal for b-cell failure. Nature. 391:846-847.
16. Ehrmann, D.A., Tang, X., Yoshiuchi, I., Cox, N.J., and Bell, G.I. 2002. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87:4297-4300.
17. Sutton, R., Peters, M., McShane, P., Gray, D.W., and Morris, P.J. 1986. Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation. 42:689-691.
18. Kushner, J.A., et al. 2002. Pdx1 restores beta cell function in Irs2 knockout mice. J. Clin. Invest. 109:1193-1201. doi:10.1172/JCI200214439.
19. Withers, D.J., et al. 1999. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat. Genet. 23:32-40.
20. Flier, S.N., Kulkarni, R.N., and Kahn, C.R. 2001. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc. Natl. Acad. Sci. U. S. A. 98:7475-7480.
21. Jhala, U.S., et al. 2003. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 17:1575-1580.
22. Previs, S.F., Withers, D.J., Ren, J.M., White, M.F., and Shulman, G.J. 2000. Contrasting effects of IRS-1 vs. IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J. Biol. Chem. 275:38990-38994.
23. Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. 1994. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature. 371:606-609.
24. Stoffers, D.A., Zinkin, N.T., Stanojevic, V., Clarke, W.L., and Habener, J.F. 1997. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat. Genet. 15:106-110.
25. -/- mice. J. Clin. Invest. 111:1147-1160. doi:10.1172/JCI200316537.
26. Ahlgren, U., Jonsson, J., Jonsson, L., Simu, K., and Edlund, H. 1998. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 12:1763-1768.
27. Yoon, J.C., et al. 2003. Suppression of beta cell energy metabolism and insulin release by PGC-1alpha. Dev. Cell. 5:73-83.
28. Matthews, D.R., et al. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412-419.
29. Hammonds, P., et al. 1990. Insulin-secreting beta-cells possess specific receptors for interleukin-1 beta. Growth Regul. 261:97-100.
30. Zumsteg, U., et al. 1993. Differential interleukin-1 receptor antagonism on pancreatic beta and alpha cells. Studies in rodent and human islets and in normal rats. Diabetologia. 36:759-766.
31. Mandrup-Poulsen, T., Bendtzen, K., Dinarello, C.A., and Nerup, J. 1987. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J. Immunol. 139:4077-4082.
32. Suarez-Pinzon, W.L., Strynadka, K., Schulz, R., and Rabinovitch, A. 1994. Mechanisms of cytokine-induced destruction of rat insulinoma cells: the role of nitric oxide. Endocrinology. 134:1006-1010.
33. Shulman, G.I. 2000. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106:171-176.
34. Reaven, G.M. 2002. Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes. Metab. 4(Suppl. 1):S13-S18.
35. Reaven, G.M. 2001. Insulin resistance: why is it important to treat? Diabetes Metab. 27:247-253.
36. White, M.F. 2002. IRS proteins and the common path to diabetes. Am. J. Physiol. Endocrinol. Metab. 283:E413-E422.
37. Clark, A., et al. 1988. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. 9:151-159.
38. Butler, A.E., et al. 2003. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52:102-110.
39. Pick, A., et al. 1998. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes. 47:358-364.
40. Herold, K.C., et al. 1996. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J. Immunol. 156:3521-3527.
41. Holstad, M., and Sandler, S. 2001. A transcriptional inhibitor of TNF-alpha prevents diabetes induced by multiple low-dose streptozotocin injections in mice. J. Autoimmun. 16:441-447.
42. Brazil, D.P., and Hemmings, B.A. 2001. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. 26:657-664.
43. Tran, H., Brunet, A., Griffith, E.C., and Greenberg, M.E. 2003. The many forks in FOXO's road. Sci. STKE. 2003:RE5.
44. Datta, S.R., et al. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:231-241.
45. Peers, B., Leonard, J., Sharma, S., Teitelman, G., and Montminy, M.R. 1994. Insulin expression in pancreatic islet cells relies on cooperative interactions between the helix loop helix factor E47 and the homeobox factor STF-1. Mol. Endocrinol. 8:1798-1806.
46. Watada, H., et al. 1996. The human glucokinase gene beta-cell-type promoter: an essential role of insulin promoter factor 1/PDX-1 in its activation in HIT-T15 cells. Diabetes. 45:1478-1488.
47. Waeber, G., Thompson, N., Nicod, P., and Bonny, C. 1996. Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor. Mol. Endocrinol. 10:1327-1334.
48. Suzuki, R., et al. 2003. Pdx1 expression in Irs2 deficient mouse beta-cells is regulated in a strain-dependent manner. J. Biol. Chem. doi:10.1074/ jbc.M307004200.
49. Vassen, L., Wegrzyn, W., and Klein-Hitpass, L. 1999. Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene. Mol. Endocrinol. 13:485-494.
50. Holst, J.J. 2002. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab. Res. Rev. 18:430-441.
51. Li, U. Y., et al. 2003. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278:471-478
52. Lugari, R., et al. 2002. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm. Metab. Res. 34:150-154.
53. Zander, M., Madsbad, S., Madsen, J.L., and Holst, J.J. 2002. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 359:824-830.
54. Farilla, L., et al. 2002. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 143:4397-4408.
55. Goss, J.A., et al. 2002. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation. 74:1761-1766.